Logo image of AVTE

AEROVATE THERAPEUTICS INC (AVTE) Stock Fundamental Analysis

NASDAQ:AVTE - Nasdaq - US0080641071 - Common Stock - Currency: USD

2.68  0 (0%)

After market: 2.6505 -0.03 (-1.1%)

Fundamental Rating

3

AVTE gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVTE as it has an excellent financial health rating, but there are worries on the profitability. AVTE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AVTE has reported negative net income.
AVTE had a negative operating cash flow in the past year.
In the past 5 years AVTE always reported negative net income.
In the past 5 years AVTE always reported negative operating cash flow.
AVTE Yearly Net Income VS EBIT VS OCF VS FCFAVTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

AVTE has a worse Return On Assets (-86.68%) than 72.34% of its industry peers.
Looking at the Return On Equity, with a value of -91.10%, AVTE is in line with its industry, outperforming 48.40% of the companies in the same industry.
Industry RankSector Rank
ROA -86.68%
ROE -91.1%
ROIC N/A
ROA(3y)-61.34%
ROA(5y)-80.96%
ROE(3y)-66.92%
ROE(5y)-110.13%
ROIC(3y)N/A
ROIC(5y)N/A
AVTE Yearly ROA, ROE, ROICAVTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

AVTE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVTE Yearly Profit, Operating, Gross MarginsAVTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

AVTE has more shares outstanding than it did 1 year ago.
AVTE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for AVTE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVTE Yearly Shares OutstandingAVTE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
AVTE Yearly Total Debt VS Total AssetsAVTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 5.98 indicates that AVTE is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.98, AVTE belongs to the best of the industry, outperforming 82.98% of the companies in the same industry.
AVTE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.98
ROIC/WACCN/A
WACCN/A
AVTE Yearly LT Debt VS Equity VS FCFAVTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

AVTE has a Current Ratio of 20.93. This indicates that AVTE is financially healthy and has no problem in meeting its short term obligations.
AVTE's Current ratio of 20.93 is amongst the best of the industry. AVTE outperforms 95.21% of its industry peers.
A Quick Ratio of 20.93 indicates that AVTE has no problem at all paying its short term obligations.
The Quick ratio of AVTE (20.93) is better than 95.21% of its industry peers.
Industry RankSector Rank
Current Ratio 20.93
Quick Ratio 20.93
AVTE Yearly Current Assets VS Current LiabilitesAVTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

AVTE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.28%, which is quite good.
EPS 1Y (TTM)15.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AVTE will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.10% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y74.29%
EPS Next 2Y-1.49%
EPS Next 3Y19.52%
EPS Next 5Y12.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVTE Yearly EPS VS EstimatesAVTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVTE. In the last year negative earnings were reported.
Also next year AVTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVTE Price Earnings VS Forward Price EarningsAVTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVTE Per share dataAVTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as AVTE's earnings are expected to grow with 19.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.49%
EPS Next 3Y19.52%

More info and screens

0

5. Dividend

5.1 Amount

AVTE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AEROVATE THERAPEUTICS INC

NASDAQ:AVTE (4/28/2025, 8:00:00 PM)

After market: 2.6505 -0.03 (-1.1%)

2.68

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/amc
Earnings (Next)05-12 2025-05-12/amc
Inst OwnersN/A
Inst Owner Change5.85%
Ins OwnersN/A
Ins Owner Change0%
Market Cap77.69M
Analysts48.89
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.62%
Min EPS beat(2)5.75%
Max EPS beat(2)25.49%
EPS beat(4)2
Avg EPS beat(4)5.57%
Min EPS beat(4)-6.37%
Max EPS beat(4)25.49%
EPS beat(8)2
Avg EPS beat(8)0.32%
EPS beat(12)3
Avg EPS beat(12)-5.75%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.64%
EPS NY rev (1m)10.65%
EPS NY rev (3m)10.65%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 1.02
EV/EBITDA N/A
EPS(TTM)-2.44
EYN/A
EPS(NY)-0.63
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0
BVpS2.64
TBVpS2.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.68%
ROE -91.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.34%
ROA(5y)-80.96%
ROE(3y)-66.92%
ROE(5y)-110.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.93
Quick Ratio 20.93
Altman-Z 5.98
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.32%
EPS Next Y74.29%
EPS Next 2Y-1.49%
EPS Next 3Y19.52%
EPS Next 5Y12.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-25.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-25.39%
OCF growth 3YN/A
OCF growth 5YN/A